Taysha Gene Therapies (TSHA) Accumulated Depreciation & Amortization (2022 - 2025)
Historic Accumulated Depreciation & Amortization for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $4.4 million.
- Taysha Gene Therapies' Accumulated Depreciation & Amortization rose 1203.37% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 1203.37%. This contributed to the annual value of $3.6 million for FY2024, which is 2030.88% up from last year.
- Taysha Gene Therapies' Accumulated Depreciation & Amortization amounted to $4.4 million in Q3 2025, which was up 1203.37% from $4.1 million recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Accumulated Depreciation & Amortization ranged from a high of $4.4 million in Q3 2025 and a low of $754000.0 during Q1 2022
- For the 4-year period, Taysha Gene Therapies' Accumulated Depreciation & Amortization averaged around $2.8 million, with its median value being $3.0 million (2023).
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 16167.11% in 2023, then surged by 1203.37% in 2025.
- Quarter analysis of 4 years shows Taysha Gene Therapies' Accumulated Depreciation & Amortization stood at $1.6 million in 2022, then soared by 81.43% to $3.0 million in 2023, then increased by 20.31% to $3.6 million in 2024, then grew by 22.35% to $4.4 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $4.4 million for Q3 2025, versus $4.1 million for Q2 2025 and $3.8 million for Q1 2025.